Baxdrostat is an investigational drug that is being evaluated for the treatment of hypertension.[1] It is an aldosterone synthase inhibitor.[2][3]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C22H25N3O2 |
Molar mass | 363.461 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Baxdrostat - CinCor Pharma". AdisInsight. Springer Nature Switzerland AG.
- ^ Dogra S, Shah S, Gitzel L, Pusukur B, Sood A, Vyas AV, Gupta R (July 2023). "Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension". Current Problems in Cardiology. 48 (11): 101918. doi:10.1016/j.cpcardiol.2023.101918. PMID 37399857. S2CID 259320969.
- ^ Awosika A, Cho Y, Bose U, Omole AE, Adabanya U (October 2023). "Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension". Expert Opinion on Investigational Drugs: 1–11. doi:10.1080/13543784.2023.2276755. PMID 37883217. S2CID 264517675.